Skip to main content
NCBI home page
Thorax logoLink to Thorax
. 1996 Jul;51(7):689–693. doi: 10.1136/thx.51.7.689

Effects of regular salmeterol on lung function and exercise capacity in patients with chronic obstructive airways disease.

A Grove 1, B J Lipworth 1, P Reid 1, R P Smith 1, L Ramage 1, C G Ingram 1, R J Jenkins 1, J H Winter 1, D P Dhillon 1
PMCID: PMC472490  PMID: 8882074

Abstract

BACKGROUND: The aim of this study was to evaluate the effects of single and chronic dosing with salmeterol on exercise capacity and lung function in patients with chronic obstructive pulmonary disease. METHODS: Twenty nine patients of mean (SE) age 64 (1.5) years, forced expiratory volume in one second (FEV1) 42(3)% of predicted, and 5-15% reversibility to salbutamol 200 micrograms were randomised to receive four weeks treatment with salmeterol 50 micrograms twice daily or placebo in a double blind crossover fashion with a one week washout period in between. Measurements of spirometric parameters, static lung volumes, and exercise capacity were made one and six hours after a single dose, and six hours after the final dose of salmeterol or placebo. RESULTS: Salmeterol produced a small increase in FEV1 at one and six hours after a single dose, and this was maintained after chronic dosing (mean difference and 95% CI versus placebo): single dosing at one hour 0.07 (95% CI 0.02 to 0.11) 1, single dosing at six hours 0.16 (95% CI 0.09 to 0.22) 1, chronic dosing at six hours 0.11 (95% CI 0.03 to 0.19) 1. The increase in forced vital capacity (FVC) was greater with salmeterol than with placebo six hours after single but not chronic dosing: single dosing at six hours 0.17 (95% CI 0.04 to 0.29) 1, chronic dosing at six hours 0.02 (95% CI -0.18 to 0.22) 1. Slow vital capacity was increased after treatment with salmeterol compared with placebo one and six hours after single but not after chronic dosing. There were no significant differences in static lung volumes or exercise capacity after single or chronic dosing with salmeterol compared with placebo. Patients reported a significantly lower Borg score for perceived exertion following the six minute walk after chronic treatment with salmeterol compared with placebo. CONCLUSIONS: Salmeterol produced a small improvement in spirometric values compared with placebo consistent with the degree of reversibility originally shown by the subjects to salbutamol 200 micrograms. This was not associated with improvements in static lung volumes or exercise capacity, but there was some symptomatic benefit in that patients were able to walk the same distance in six minutes with less perceived exertion.

Full text

PDF
689

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bellamy D., Hutchison D. C. The effects of salbutamol aerosol on lung function in patients with pulmonary emphysema. Br J Dis Chest. 1981 Apr;75(2):190–196. doi: 10.1016/0007-0971(81)90052-8. [DOI] [PubMed] [Google Scholar]
  2. Belman M. J. Exercise in patients with chronic obstructive pulmonary disease. Thorax. 1993 Sep;48(9):936–946. doi: 10.1136/thx.48.9.936. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Berger R., Smith D. Effect of inhaled metaproterenol on exercise performance in patients with stable "fixed" airway obstruction. Am Rev Respir Dis. 1988 Sep;138(3):624–629. doi: 10.1164/ajrccm/138.3.624. [DOI] [PubMed] [Google Scholar]
  4. Connellan S. J., Gough S. E. The effects of nebulized salbutamol on lung function and exercise tolerance in patients with severe airflow obstruction. Br J Dis Chest. 1982 Apr;76(2):135–142. [PubMed] [Google Scholar]
  5. Corris P. A., Neville E., Nariman S., Gibson G. J. Dose-response study of inhaled salbutamol powder in chronic airflow obstruction. Thorax. 1983 Apr;38(4):292–296. doi: 10.1136/thx.38.4.292. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Dahl R., Earnshaw J. S., Palmer J. B. Salmeterol: a four week study of a long-acting beta-adrenoceptor agonist for the treatment of reversible airways disease. Eur Respir J. 1991 Nov;4(10):1178–1184. [PubMed] [Google Scholar]
  7. Evald T., Keittelmann S., Sindrup J. H., Lange P. The effect of inhaled terbutaline on FEV1, FVC, dyspnoea and walking distance in patients with chronic obstructive lung disease. Respir Med. 1992 Mar;86(2):93–96. doi: 10.1016/s0954-6111(06)80221-0. [DOI] [PubMed] [Google Scholar]
  8. Guyatt G. H., Townsend M., Pugsley S. O., Keller J. L., Short H. D., Taylor D. W., Newhouse M. T. Bronchodilators in chronic air-flow limitation. Effects on airway function, exercise capacity, and quality of life. Am Rev Respir Dis. 1987 May;135(5):1069–1074. doi: 10.1164/arrd.1987.135.5.1069. [DOI] [PubMed] [Google Scholar]
  9. Lipworth B. J., Clark R. A., Dhillon D. P., McDevitt D. G. Comparison of the effects of prolonged treatment with low and high doses of inhaled terbutaline on beta-adrenoceptor responsiveness in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis. 1990 Aug;142(2):338–342. doi: 10.1164/ajrccm/142.2.338. [DOI] [PubMed] [Google Scholar]
  10. Morgan A. D., Peck D. F., Buchanan D. R., McHardy G. J. Effect of attitudes and beliefs on exercise tolerance in chronic bronchitis. Br Med J (Clin Res Ed) 1983 Jan 15;286(6360):171–173. doi: 10.1136/bmj.286.6360.171. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Newnham D. M., Dhillon D. P., Winter J. H., Jackson C. M., Clark R. A., Lipworth B. J. Bronchodilator reversibility to low and high doses of terbutaline and ipratropium bromide in patients with chronic obstructive pulmonary disease. Thorax. 1993 Nov;48(11):1151–1155. doi: 10.1136/thx.48.11.1151. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Spiro S. G., Juniper E., Bowman P., Edwards R. H. An increasing work rate test for assessing the physiological strain of submaximal exercise. Clin Sci Mol Med. 1974 Feb;46(2):191–206. doi: 10.1042/cs0460191. [DOI] [PubMed] [Google Scholar]
  13. Swinburn C. R., Wakefield J. M., Jones P. W. Performance, ventilation, and oxygen consumption in three different types of exercise test in patients with chronic obstructive lung disease. Thorax. 1985 Aug;40(8):581–586. doi: 10.1136/thx.40.8.581. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Taylor D. R., Buick B., Kinney C., Lowry R. C., McDevitt D. G. The efficacy of orally administered theophylline, inhaled salbutamol, and a combination of the two as chronic therapy in the management of chronic bronchitis with reversible air-flow obstruction. Am Rev Respir Dis. 1985 May;131(5):747–751. doi: 10.1164/arrd.1985.131.5.747. [DOI] [PubMed] [Google Scholar]
  15. Tweeddale P. M., Alexander F., McHardy G. J. Short term variability in FEV1 and bronchodilator responsiveness in patients with obstructive ventilatory defects. Thorax. 1987 Jul;42(7):487–490. doi: 10.1136/thx.42.7.487. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Ullman A., Svedmyr N. Salmeterol, a new long acting inhaled beta 2 adrenoceptor agonist: comparison with salbutamol in adult asthmatic patients. Thorax. 1988 Sep;43(9):674–678. doi: 10.1136/thx.43.9.674. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES